Association Between Achievement of Clinical Disease Control and Improvement in Patient‐Reported Outcomes and Quality of Life in Patients With Psoriatic Arthritis in the Phase 3 SELECT‐PsA 1 and 2 Randomized Controlled Trials

Documenti analoghi

• Control of Inflammation and Sustained Improvements in Patient‐Reported Outcomes in Patients With Psoriatic Arthritis: Bimekizumab Two‐Year Results From Two Phase 3 Studies
  di: Laure Gossec, et al.
  Pubblicazione: (2026)
• Improvements in Patient‐Reported Outcomes Through Six Months of Guselkumab Treatment in Patients With Active Psoriatic Arthritis: Real‐World Data From the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry
  di: Philip J. Mease, et al.
  Pubblicazione: (2024)
• What Matters in Psoriatic Arthritis: A Comparison of Patient and Clinician Perspectives
  di: Philip J. Mease, et al.
  Pubblicazione: (2025)
• Efficacy and Safety of Bimekizumab in Patients With Psoriatic Arthritis With or Without Methotrexate: 52‐Week Results From Two Phase 3 Studies
  di: Iain B. McInnes, et al.
  Pubblicazione: (2024)
• Impact of Delay of Treatment With Disease‐Modifying Antirheumatic Drugs in Psoriatic Arthritis: The CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry
  di: Philip J. Mease, et al.
  Pubblicazione: (2025)